# Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.

> **NCT04682444** · PHASE2,PHASE3 · COMPLETED · sponsor: **Joint Stock Company "Farmak"** · enrollment: 100 (actual)

## Conditions studied

- Acute Respiratory Viral Infections
- Human Influenza

## Interventions

- **DRUG:** Enisamium Iodide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04682444
- **Lead sponsor:** Joint Stock Company "Farmak"
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-13
- **Primary completion:** 2010-01-15
- **Final completion:** 2010-01-15
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04682444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04682444, "Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04682444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*